Spasticity therapy reacts to astrocyte GluA1 receptor upregulation following spinal cord injury

British Journal of Pharmacology

Volumn 161, Issue 5, 2010, Pages 972-975

  Gómez Soriano, Julio ^a   Goiriena, Eider ^a   Taylor, Julian ^a  

^a HOSPITAL NACIONAL DE PARAPLÉJICOS   (Spain)

Author keywords

AMPA; Astrocyte; Baclofen tolerance; Baclofen withdrawal syndrome; GABA; Glutamate A1 receptor; Ischaemia; Spasticity; Spinal cord injury

Indexed keywords

AMPA RECEPTOR; AMPA RECEPTOR ANTAGONIST; BACLOFEN; GLUTAMATE RECEPTOR; GLUTAMATE RECEPTOR A1; NGX 424; TEZAMPANEL; UNCLASSIFIED DRUG;

ASTROCYTE; DRUG RECEPTOR BINDING; ELECTROMYOGRAPHY; HUMAN; MUSCLE REFLEX; MUSCLE STRETCHING; MUSCLE WEAKNESS; NONHUMAN; NOTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPASTICITY; SPINAL CORD INJURY; UPREGULATION; WITHDRAWAL SYNDROME;

ANIMALS; ASTROCYTES; BACLOFEN; HUMANS; INJECTIONS, SPINAL; ISOQUINOLINES; MUSCLE RELAXANTS, CENTRAL; MUSCLE SPASTICITY; RECEPTORS, AMPA; SPINAL CORD INJURIES; SUBSTANCE WITHDRAWAL SYNDROME; TETRAZOLES; UP-REGULATION;

EID: 77958527890     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.00964.x     Document Type: Note

References (16)

1. Adams MM, Hicks AL (2005). Spasticity after spinal cord injury. Spinal Cord 43: 577-586.
2. Alexander SPH, Mathie A, Peters JA (2009). Guide to Receptors and Channels (GRAC), 4th edition. Br J Pharmacol 158 (Suppl. 1): S1-S254.
3. Bennett DJ (2008). Demystifying spasticity: reply to Dietz. J Neurophysiol 99: 1041-1043.
4. Dario A, Tomei G (2004). A benefit-risk assessment of baclofen in severe spinal spasticity. Drug Saf 27: 799-818.
5. Farkas S, Ono H (1995). Participation of NMDA and non-NMDA excitatory amino acid receptors in the mediation of spinal reflex potentials in rats: an in vivo study. Br J Pharmacol 114: 1193-1205.
6. Gómez-Soriano J, Castellote JM, Pérez-Rizo E, Esclarín A, Taylor JS (2010). Voluntary ankle flexor activity and adaptive coactivation gain is decreased by spasticity during subacute spinal cord injury. Exp Neurol 224: 507-516.
7. Heetla HW, Staal MJ, Kliphuis C, Van Laar T (2009). The incidence and management of tolerance in intrathecal baclofen therapy. Spinal Cord 47: 751-756.
8. Hefferan MP, Kucharova K, Kinjo K, Kakinohana O, Sekerkova G, Nakamura S et al. (2007). Spinal astrocyte glutamate receptor 1 overexpression after ischemic insult facilitates behavioral signs of spasticity and rigidity. J Neurosci 27: 11179-11191.
9. Hiersemenzel LP, Curt A, Dietz V (2000). From spinal shock to spasticity: neuronal adaptations to a spinal cord injury. Neurology 54: 1574-1582.
10. Kawasaki Y, Zhang L, Cheng JK, Ji RR (2008). Cytokine mechanisms of central sensitization: distinct and overlapping role of interleukin-1beta, interleukin-6, and tumor necrosis factor-alpha in regulating synaptic and neuronal activity in the superficial spinal cord. J Neurosci 28: 5189-5194.
11. Mohammed I, Hussain A (2004). Intrathecal baclofen withdrawal syndrome - a life-threatening complication of baclofen pump: a case report. BMC Clin Pharmacol 4: 6.
12. Oshiro M, Hefferan MP, Kakinohana O, Lukacova N, Yaksh TL, Marsala M (2010). Suppression of stretch reflex activity after spinal or systemic treatment with AMPA receptor antagonist NGX424 in rats with developed baclofen tolerance. Br J Pharmacol 161: 976-985.
13. Taylor JS, Friedman RF, Munson JB, Vierck CJ Jr (1997). Stretch hyperreflexia of triceps surae muscles in the conscious cat after dorsolateral spinal lesions. J Neurosci 17: 5004-5015.
14. Taylor J, Munson J, Vierck C Jr (1999). Effects of dorsolateral spinal lesions on stretch reflex threshold and stiffness in awake cats. Eur J Neurosci 11: 363-368.
15. Turski L, Jacobsen P, Honore T, Stephens DN (1992). Relief of experimental spasticity and anxiolytic/anticonvulsant actions of the alpha-amino-3-hydroxy-5-methyl-4--isoxazolepropionate antagonist 2, 3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline. J Pharmacol Exp Ther 260: 742-747.
16. Wrathall JR, Teng YD, Marriott R (1997). Delayed antagonism of AMPA/kainate receptors reduces long-term functional deficits resulting from spinal cord trauma. Exp Neurol 145: 565-573.